This activity is supported by educational grants from AbbVie Inc.; Bristol Myers Squibb; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Takeda Pharmaceuticals U.S.A., Inc.

Chip leader Nova stock is breaking out past its latest buy point following a string of big gains in heavy volume.

MakeMyTrip (NASDAQ:MMYT) is an ttractive stock for investors looking for exposure to India, one of Earth’s fastest-growing, best-positioned countries. Indeed, the country’s economy is expected to grow ...

A Teva Pharmaceuticals drug being developed in partnership with Sanofi to hit a promising but competitive target for inflammation now has positive data from a clinical test in the two most common ...

AbbVie has become the latest Big Pharma to jump on the anti-TL1A train, paying China’s FutureGen Biopharmaceutical $150 million upfront for a preclinical inflammatory bowel disease (IBD) candidate.

Roche’s Genentech unit has handed over $20 million in upfront cash for the license to Omass Therapeutics’ preclinical inflammatory bowel disease (IBD) program. The program is the product of Omass’ ...